We’re Hiring! View Open Positions

About Us

Our collaboration with people affected by rare diseases makes bold science possible.

A nimble and unique organization, Enzyvant has a full range of capabilities spanning non-clinical and clinical development and commercialization and is developing in-house manufacturing.

We prioritize collaborative connections with patients, caregivers, academia, industry, associations, advocacy and the government to accelerate transformative medicines that are urgently needed.

We are purpose-driven and we do not give up, choosing the biggest challenges impacting the rare disease community today. We adapt. We follow through and we succeed. Because in rare diseases, the communities are small and the human need is immense.

Our Global Network

Enzyvant is part of Sumitovant Biopharma (wholly owned by Sumitomo Pharma), a global ecosystem of companies working on innovative research and development activities to transform healthcare and improve the lives of people worldwide. This global ecosystem has a geographic footprint spanning Japan, the United States, China and the EU as well as talent, knowledge and resources across a wide spectrum of technologies and therapeutic areas. Enzyvant benefits from this substantial Sumitomo Pharma support structure as we work to urgently develop and commercialize transformative regenerative therapies for rare diseases. 

Global network map

Contact us for more information